Apollon Formularies plc Grand Opening of International Cancer Institute (5360A)
February 03 2022 - 1:59AM
UK Regulatory
TIDMAPOL
RNS Number : 5360A
Apollon Formularies plc
03 February 2022
3 February 2022
Apollon Formularies Plc
Grand Opening of International Cancer and Chronic Pain
Institute
Apollon Formularies plc (AQSE: APOL, "Apollon" or the
"Company"), a UK based international medical cannabis
pharmaceutical company trading on the Aquis Stock Exchange Growth
Market, is pleased to announce that it has officially opened its
International Cancer and Chronic Pain Institute ("ICCPI") in the
Jamaican capital and country's key medical hub, Kingston. The
facility will specialise in Complementary and Alternative Medical
treatments ("CAM") for cancer patients. These treatments will
include Apollon's medical cannabis products.
This facility allows Apollon to expand its patient treatment
programme for both Jamaican and international medical patients, and
at the same time generate additional revenue for the Company.
Apollon is pleased to add that the Company is experiencing
demand from international patients who wish to be treated in
Jamaica and will be admitting its second UK patient in mid-February
2022.
The ICCPI also provides the opportunity to gather invaluable
patient data on the Company's medical cannabis formulations.
In December 2021, Apollon welcomed its first cancer patients to
its existing facilities in Jamaica and is now able to provide
expanded access via two facilities located in Negril and Kingston.
In addition to treating international and local Jamaican patients,
the ICCPI physicians will shortly initiate clinical trials on
Apollon's proprietary medical cannabis products through Apollon's
research and development license with oversight from the Ministry
of Health and Wellness in Jamaica.
Paul Burke, CEO Apollon Formularies Jamaica, commented: "Our
International Cancer Institute is one of a kind and I am proud to
see our hard work pay off. Following our remarkable 3D cell culture
test results and the expansion of our production facility, this
next step will help Apollon compete on a world class level whilst
providing our patients with the treatment and expert care
needed."
Hon. Dr. Norman Dunn MP, State Minister in the Ministry of
Industry, Investment and Commerce, commented: "It is my great
pleasure to be part of today's landmark occasion for Apollon
Formularies as you open Jamaica's first International Cancer and
Chronic Pain Institute which has been established to offer
complimentary plant-based medicine and to carry on clinical trials
on cancer treatment formulations. From all accounts, their
formulations have undergone rigorous third-party testing from
esteemed pharmaceutical testing labs. I want to congratulate in
particular Dr Stephen Barnhill and Dr Dingel Spence, Paul Burke and
the rest of the team here at Apollon Formularies for your vision,
tenacity and entrepreneurial spirit."
Dr Stephen Barnhill, CEO of Apollon Formularies, commented: "I
am glad to see the progress we have made as a Company come to
fruition in the official opening of this impressive Cancer
Institute. The facility will provide us with the opportunity to
admit patients and use our proprietary formulations to treat common
cancers. I would like to take this opportunity to thank the team on
the ground in Jamaica who has helped make this happen."
ENDS
The Directors of the Company accept responsibility for the
contents of this announcement.
For additional information, please visit www.apollon.org.uk or
contact:
Apollon Formularies
Tel: +44 771 198 0221
Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
Blytheweigh (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe tim.blythe@blytheweigh.com
Megan Ray megan.ray@blytheweigh.com
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis
company headquartered in the United Kingdom. Apollon Formularies
Jamaica Limited is a pharmaceutical company incorporated and
operating in the Commonwealth of Jamaica. Apollon Jamaica is
licensed by the Jamaican government's Cannabis Licensing Authority
(CLA) to cultivate, perform research and development, process, and
sell medical cannabis therapeutic products that include legal
medical cannabis in order to treat various illnesses under medical
supervision. Apollon and Apollon Jamaica are parties to a
Commitment Agreement whereby Apollon is entitled to 95% of Apollon
Jamaica's Net Profits, and per a Stock Pledge Agreement that
includes Stephen D. Barnhill, M.D., Apollon is to be assigned the
entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill,
which is the maximum interest in a medical cannabis company allowed
to be held by a non-Jamaican, upon the CLA approving the
assignment.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXMZGGZZZRGZZZ
(END) Dow Jones Newswires
February 03, 2022 01:59 ET (06:59 GMT)
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Apr 2023 to Apr 2024